Compare LGL & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | VNRX |
|---|---|---|
| Founded | 1917 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | LGL | VNRX |
|---|---|---|
| Price | $5.78 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.17 |
| AVG Volume (30 Days) | 8.7K | ★ 2.8M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 149.85 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $4,107,000.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | N/A | $493.79 |
| P/E Ratio | $33.79 | ★ N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $5.45 | $0.27 |
| 52 Week High | $9.74 | $0.94 |
| Indicator | LGL | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 28.10 |
| Support Level | $5.59 | $0.28 |
| Resistance Level | $5.99 | $0.31 |
| Average True Range (ATR) | 0.25 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 44.93 | 3.77 |
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.